HRAS antibody (AA 104-128)
-
- Target See all HRAS Antibodies
- HRAS (HRas proto-oncogene, GTPase (HRAS))
-
Binding Specificity
- AA 104-128
-
Reactivity
- Human
-
Host
- Rabbit
-
Clonality
- Polyclonal
-
Conjugate
- This HRAS antibody is un-conjugated
-
Application
- Western Blotting (WB), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
- Predicted Reactivity
- M, Rat
- Purification
- This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
- Immunogen
- This HRAS antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 104-128 amino acids from the Central region of human HRAS.
- Clone
- RB15622
- Isotype
- Ig Fraction
- Top Product
- Discover our top product HRAS Primary Antibody
-
-
- Application Notes
- IF: 1:10~50. WB: 1:1000. WB: 1:500. IHC-P: 1:10~50
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
- Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
- Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C,-20 °C
- Storage Comment
- Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
- Expiry Date
- 6 months
-
-
Mutational analysis of HRAS and KRAS genes in oral carcinoma cell lines." in: Odontology / the Society of the Nippon Dental University, Vol. 100, Issue 2, pp. 149-55, (2012) (PubMed).
: "p66(Shc) restrains Ras hyperactivation and suppresses metastatic behavior." in: Oncogene, Vol. 29, Issue 41, pp. 5559-67, (2010) (PubMed).
: "
-
Mutational analysis of HRAS and KRAS genes in oral carcinoma cell lines." in: Odontology / the Society of the Nippon Dental University, Vol. 100, Issue 2, pp. 149-55, (2012) (PubMed).
-
- Target
- HRAS (HRas proto-oncogene, GTPase (HRAS))
- Alternative Name
- HRAS (HRAS Products)
- Background
- HRAS belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. These proteins function in signal transduction pathways. They can bind GTP and GDP, and they have intrinsic GTPase activity. HRAS undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Mutations in this gene cause Costello syndrome, a disease characterized by increased growth at the prenatal stage, growth deficiency at the postnatal stage, predisposition to tumor formation, mental retardation, skin and musculoskeletal abnormalities, distinctive facial appearance and cardiovascular abnormalities. Defects in the HRAS gene are implicated in a variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma.
- Molecular Weight
- 21298
- Gene ID
- 3265
- NCBI Accession
- NP_001123914, NP_005334, NP_789765
- UniProt
- P01112
- Pathways
- p53 Signaling, MAPK Signaling, RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Hepatitis C, Autophagy, Signaling Events mediated by VEGFR1 and VEGFR2, Signaling of Hepatocyte Growth Factor Receptor, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling, BCR Signaling
-